IP Library › Granted Patent US 9,986,942
Granted Patent B2
US 9,986,942 · App. 11/503,367 · Granted Jun 5, 2018

Analyte sensor

Inventors: James H. Brauker (San Diego, CA); Robert Boock (San Diego, CA); Monica Rixman (San Diego, CA); Peter C. Simpson (Encinitas, CA); Mark Brister (Encinitas, CA); Mark Shults (Madison, WI)
Assignee: DexCom, Inc.
A61B5/14865A61B5/14532A61B5/411A61B5/6848C12Q1/006G01N33/54366G01N33/66A61B5/1473A61B5/418A61B2562/08
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,986,942
App. No.
11/503,367
Filed
Aug 10, 2006
Granted
Jun 5, 2018
Kind
B2
Art Unit
3735
USPC
600/365
Abstract

Biointerface membranes are provided which can be utilized with implantable devices, such as devices for the detection of analyte concentrations in a biological sample. More particularly, methods for monitoring glucose levels in a biological fluid sample using an implantable analyte detection device incorporating such membranes are provided.

Claims (9)

1. An analyte sensing device for detecting an analyte in a host, comprising:

a transcutaneous continuous sensor configured to measure a clinically useful analyte concentration in a tissue of a host for a time period from one day to fifteen days post implantation, the sensor comprising:

a sensor configured to measure an analyte in a host;

a sensing membrane located over the sensor; and

a biointerface membrane disposed on the sensing membrane, wherein the biointerface membrane is configured to interface with biological fluid, wherein the biointerface membrane has a dry thickness from 0.2 microns to 5 microns, wherein the biointerface membrane comprises a material that has from 20 wt. % to about 80 wt. % water during sensor use,

wherein the sensor has a sensitivity of 1 pA/mg/dL to 100 pA/mg/dL during a sensor session.

2. The device of claim 1 , wherein the biointerface membrane comprises a bioactive agent, wherein the bioactive agent comprises a substance that releases into the tissue upon implantation into the host, wherein the bioactive agent suppresses wound healing by promoting irritation and/or inflammation around at least a portion of the sensor in vivo.

3. The device of claim 1 , wherein the biointerface membrane comprises a shape-memory material configured to be applied to the sensor in a first configuration, wherein after insertion into the tissue of the host the shape-memory material is configured to transform to a second configuration.

4. The device of claim 1 , wherein the biointerface membrane comprises an irritating architecture configured to promote fluid bulk surrounding at least a portion of the sensor in vivo by promoting an irritation and/or inflammation surrounding the sensor in vivo, thereby discouraging cells from stabilizing and building up an ordered, fibrous capsule during the time period.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 2, 2007
From: SHULTS, MARK
To: DEXCOM, INC.
Reel/Frame 018848/0455 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 11, 2006
From: BRAUKER, JAMES H.; BOOCK, ROBERT; RIXMAN, MONICA; SIMPSON, PETER C.; BRISTER, MARK
To: DEXCOM, INC.
Reel/Frame 018378/0627 →
Continuity (8)
Continuation In Part 11439630 · May 23, 2006
Continuation In Part 11077715 · Mar 10, 2005
Provisional Application 60587787 · Jul 13, 2004
Provisional Application 60587800 · Jul 13, 2004
Provisional Application 60614683 · Sep 30, 2004
Provisional Application 60614764 · Sep 30, 2004
Provisional Application 60683923 · May 23, 2005
Related Publication 20070027370A1 · Feb 1, 2007